Atopic dermatitis (AD) is often associated with other atopic diseases, including asthma, allergic rhinitis, atopy-associated eye disorders, and eosinophilic esophagitis. Depression and anxiety are also comorbidities to AD that significantly affect quality of life and should be screened for in patients with AD. Links to other comorbidities such as cardiovascular disease and malignancy are considered inconclusive, but patient counselling and screening may be appropriate in some patients. This article highlights practical recommendations for the recognition and management of atopic and nonatopic comorbidities commonly associated with AD.
Atopic diseases are very common in both children and adults, and while both incidence and prevalence are well documented in children, the true prevalence of these diseases is less well known in the adult population. Most cases of atopic dermatitis (AD) are commonly believed to be early onset, appearing in the first 2 years of life and improving with age. 1 In the United States, self-reported pediatric AD is reported to be 10.7%. 2 In contrast, adult-onset AD is thought to be much less common, and few epidemiological studies have documented its prevalence. 1 Importantly, rates of AD prevalence in adults vary widely depending on geography, likely due to varied diagnostic criteria and international differences in clinical phenotype.
Several publications have attempted to document the true prevalence of AD in adults. Using population-based data from the US National Center for Health Statistics and the Centers for Disease Control and Prevention, the prevalence of eczema was found to be 10.2% in adults. 3 Furthermore, a 3.2% prevalence of eczema, asthma, and hay fever was identified, suggesting AD is not uncommon in adult patients. 3, 4 A large, international, web-based survey done in the United States, Canada, Europe, and Japan showed patient-reported rates of adult AD between 2.1% and 4.9%, most commonly of mild-to-moderate severity. 5 Of note, the point prevalence of AD in Canada was found to be 3.5%. A population-based Italian study estimated an 8.1% prevalence of self-reported eczema, with a 3.4% prevalence of eczema with asthma and/ or hay fever. Prevalence was significantly associated with environmental factors, which included living close to industrial plants and high levels of heavy traffic near home. 6 Interestingly, a recent systematic review and meta-analysis suggests that there is no significant difference in AD prevalence before and after childhood. 7 This may be due to persistent disease, remission, or clearance of disease among some patients and late-onset disease in others.
AD is often associated with other atopic diseases and may occur as part of the atopic march. Atopic diseases include asthma, allergic rhinitis, atopy-associated eye disorders including allergic conjunctivitis and keratoconjunctivitis, Original Article and eosinophilic esophagitis. 8 In particular, allergic diseases such as allergic rhinitis, asthma, and food allergies have been increasing in industrial societies, with some studies showing a prevalence of up to 42% for allergic rhinitis, 20% for asthma, and 10% for food allergy in developed areas. [9] [10] [11] The increase in allergic diseases may be explained in part by the hygiene hypothesis, where reduced microbial burden during childhood predisposes individuals to type 2-mediated diseases. 12 AD often precedes the development of allergic rhinitis, asthma, and food allergy. In patients who develop allergy, AD is often the first presenting disease. 13, 14 The predominant hypothesis for this development is that a defect in skin barrier function allows type 2 inflammatory responses against respiratory environmental, food, and bacterial allergens in susceptible individuals. [15] [16] [17] This results in multiple IgE sensitization and high IgE, the consequence of which is the development of atopy and allergic disease.
Early intervention to preserve and protect the skin barrier may prevent the development of AD, as it may reduce allergic sensitization. This includes early use of skin emollients and moisturizers as well as the use of vitamin D. [18] [19] [20] [21] Furthermore, effective treatment of AD may prevent the atopic march by restoring skin barrier function, reducing allergic sensitization, and reducing type 2 inflammation.
Importantly, allergic airway disease is often underdiagnosed, both in the general population and in patients with AD. As it is more common in patients with AD, a careful history of wheezing should be taken. Eosinophilic esophagitis should be considered in atopic patients if there are persistent upper gastrointestinal (GI) symptoms such as dysphagia and food impaction. Inhalant allergy testing may be helpful if there is a history of contact urticaria/ dermatitis after allergen exposure (especially furry animals) or history of immediate-type airway and/or eye symptoms. Patients with AD are more likely to have positive patch tests to fragrances, rubbers, emollients, and external drugs, including topical steroids. Routine food allergen testing in patients without a history of immediatetype symptoms is not necessary and is associated with many false-positive test results. 8 Depression and anxiety are also important comorbidities to AD that significantly affect quality of life (QoL). A study comparing psychiatric comorbidities in AD found that hospitaldiagnosed depression is significantly higher in patients with AD and, in particular, in patients with severe AD compared to the general population. 22 In addition, the prevalence of anxiety in patients with AD is higher compared to the general population, an observation paralleled by anxiolytic use. 22 Increased depression and anxiety in AD have also been reported in several cohort studies. A large cohort study of military conscripts in South Korea found an increased risk of depression, anxiety, and somatization in young adult males, with moderate-to-severe AD having a greater impact on both depression and somatization. 23 Likewise, a study using the Taiwan National Health Insurance Research Database found higher incidences of major depression and anxiety in both adult and adolescent populations with AD compared to age-and sex-matched controls. 24 Interestingly, a Finnish twin study in adults found a small shared genetic risk for atopic disease and depressive symptoms. 25 Increasing evidence for the role of neuroinflammation and cytokine signalling in psychiatric diseases may support the hypothesis that immune dysregulation in AD plays a contributing role in the development of comorbid depression and anxiety. 24, 26 In light of this evidence, health care providers should consider using screening tools to assess depression and anxiety in patients with AD and refer to appropriate specialists as necessary.
Ocular comorbidities are common in patients with AD and involve complex factors contributing to pathophysiology. [27] [28] [29] Ocular disorders associated with AD include atopic keratoconjunctivitis (AKC), blepharitis, iritis, cataracts, keratoconus, and retinal detachment. 27, 28, 30 In addition, diagnostic criteria by Hanifin and Rajka 31 include minor criteria of recurrent conjunctivitis, anterior cataracts, and keratoconus. [30] [31] [32] AKC is the most common ocular comorbidity in patients with AD, occurring in 20% to 40% of patients. 27 Symptoms include chronic itching, tearing, burning, pain, and ropy discharge. 27, 33 Signs include severe eczema of the eyelids and periorbital skin, chronic inflammation of the conjunctiva, corneal erosion, ulceration and mucous plaques, and tear dysfunction. 28 Early recognition and appropriate management of ocular comorbidities are important to prevent long-term sequelae and disability. As conjunctivitis is common in patients with AD, health care providers should have an understanding of the diagnosis, management, and referral of these patients. Health care providers should be comfortable managing mild conjunctivitis as well as recognizing signs and symptoms that require referral or urgent care. Importantly, steroid use in the eye should be used with caution, and ocular herpes simplex virus infection should be ruled out prior to initiation of steroid eye drops. Gooderham et al 34 provide a practical guide for dermatologists to manage conjunctivitis, and the reader is referred to this guideline for a more detailed discussion and management algorithm. Where necessary, health care providers should consider managing patients with AD experiencing ocular symptoms in collaboration with an ophthalmologist or other eye health specialist.
The association between AD and malignancy remains inconclusive. There is insufficient evidence to recommend cancer-specific screening in patients with AD; however, patients may benefit from counselling about modifiable risk factors such as sun exposure and smoking. Limited evidence includes case-control studies and retrospective reviews, [35] [36] [37] [38] and results should be interpreted with caution due to confounders such as smoking, ultraviolet treatments, and immunosuppressive therapies. Cancer associations reported in the literature include lymphoma; pancreatic, esophageal, lung, and brain cancers; cervical high-risk human papilloma virus infection; and nonmelanoma skin cancer. 37, 38 The evidence for cardiovascular (CV) risk in patients with AD is controversial. Patients with CV risk factors may benefit from behavioural modification and referral to a family physician. There are conflicting results regarding the association of AD to CV disease and stroke. [39] [40] [41] [42] [43] [44] [45] It is also important to note that several of these studies are not reflected in the clinical experiences of dermatology experts in Canada. Indeed, a recent Canadian study found no positive association between AD and CV disease or stroke after adjusting for confounders. 45 Despite the scant evidence to draw firm links between AD and malignancy and CV risk, health care providers are encouraged to perform appropriate history taking and physical exams, as well as to enlist the assistance of a primary care provider if indicated.
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